Commercialization And Logistics

  1. An Active Release Mechanism For Magnetic Separation And Cell Isolation 11/13/2023

    Discover an innovative active release solution that will serve autologous and allogeneic processes to the benefit of cell therapy patients.

  2. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  3. Pipeline Progress 8/18/2023

    Experts working on robust pipelines that focus on various therapeutic areas explain how process automation looks different per therapeutic focus area.

  4. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.

  5. mRNA For Cancer Immunotherapy 2024 Outlook | Audience Q&A 1/29/2024

    During our Cell & Gene Live, mRNA For Cancer Immunotherapy 2024 Outlook, our expert panelists answered audience questions regarding patient safety, foreseeable challenges in mRNA cancer immunotherapy for solid tumors, and much more.

  6. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  7. Planning for Success: Supply Resiliency Strategies for Bench to Production 10/18/2023

    Build scalable material sourcing strategies for R&D and early phases through to commercialization and learn how to accelerate the development process and ensure the scalability of your biologics.

  8. Improvements In Scaling And Sequencing For Allogeneic Cell Therapies For Oncology 5/6/2024

    During this segment, Nguyen and Wagner agree that scalability will be a top concern for most CGT companies.

  9. Upstream To Downstream: A Comprehensive Approach To AAV Production 12/7/2023

    How can you face the challenges of AAV production, scale up your AAV manufacturing effectively, and enhance the recovery and purity in your downstream processing.

  10. Quality Roundtable: Optimizing Biologics Manufacturing Processes With Raw Materials 1/24/2024

    Improve your commercial manufacturing process with advice from regulatory and raw materials experts on the development journey from pre-clinical to licensure.